Back to Diseases List
Associated Genetic Biomarkers
Oral neoplasms most frequently harbor alterations in TP53, CDKN2A, NOTCH1, PIK3CA, and KMT2D .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, CDKN2A Mutation, and PIK3CA Mutation are the most common alterations in oral neoplasm .
There is 1 clinical trial for oral neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains oral neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
del(11)(p10), del(13)(q10), and del(17)(p10) are the most frequent gene inclusion criteria for oral neoplasm clinical trials .
Avelumab is the most common intervention in oral neoplasm clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.